ABI-007 in the treatment of unresectable or recurrent gastric cancer refractory to fluoropyrimidine-containing regimen: Updated data from the multicenter phase II study.

被引：2
|
作者：
Takiuchi, Hiroya
Sasaki, Yasutsuna
Nishina, Tomohiro
Yasui, Hirofumi
Muro, Kei
Tsuji, Akihito
Koizumi, Wasaburo
Toh, Yasushi
Hara, Takuo
Miyata, Yoshinori
机构：
[1] Osaka Med Coll, Osaka, Japan
[2] Saitama Med Univ, Int Med Ctr, Saitama, Japan
[3] Natl Hosp Org, Shikoku Canc Ctr, Matsuyama, Ehime, Japan
[4] Shizuoka Canc Ctr, Shizuoka, Japan
[5] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[6] Kochi Hlth Sci Ctr, Kochi, Japan
[7] Kitasato Univ, Sagamihara, Kanagawa, Japan
[8] Natl Kyusyu Canc Ctr, Fukuoka, Japan
[9] Kouseiren Takaoka Hosp, Takaoka, Toyama, Japan
[10] Saku Cent Hosp, Nagano, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 04期
关键词：
D O I：
10.1200/jco.2012.30.4_suppl.90
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
90
引用
收藏
页数：2
相关论文
共 50 条
  • [41] AN OPEN-LABEL PHASE II STUDY OF TREATMENT WITH SUNITINIB IN PATIENTS SUFFERING FROM METASTATIC CASTRATED REFRACTORY PROSTATE CANCER (CRPC) AFTER PROGRESSION WITH DOCETAXEL-BASED REGIMEN
    Oudard, S. M.
    Caty, A.
    Rolland, F.
    Sevin, E.
    Gravis, G.
    Priou, F.
    Eymard, J.
    Gillaizeau, F.
    Brizard, M.
    Beuzeboc, P.
    ANNALS OF ONCOLOGY, 2010, 21 : 276 - 276
  • [42] Multicenter, randomized, open-label Phase II study comparing S-1 alternate-day oral therapy with the standard daily regimen as a first-line treatment in patients with unresectable advanced pancreatic cancer
    Yamaue, Hiroki
    Shimizu, Atsushi
    Hagiwara, Yasuhiro
    Sho, Masayuki
    Yanagimoto, Hiroaki
    Nakamori, Shoji
    Ueno, Hideki
    Ishii, Hiroshi
    Kitano, Masayuki
    Sugimori, Kazuya
    Maguchi, Hiroyuki
    Ohkawa, Shinichi
    Imaoka, Hiroshi
    Hashimoto, Daisuke
    Ueda, Kazuki
    Nebiki, Hiroko
    Nagakawa, Tatsuya
    Isayama, Hiroyuki
    Yokota, Isao
    Ohashi, Yasuo
    Shirasaka, Tetsuhiko
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (04) : 813 - 823
  • [43] Phase II trial of nab-paclitaxel plus ramucirumab in combination with nivolumab for unresectable advanced or recurrent gastric cancer after progression on first-line treatment including fluoropyrimidine, platinum, and anti-PD-1/PD-L1 antibody (PADDLE)
    Hirano, Hidekazu
    Takahashi, Naoki
    Amanuma, Yusuke
    Suzuki, Nobumi
    Takahari, Daisuke
    Kawakami, Takeshi
    Kudo-Saito, Chie
    Nagashima, Kengo
    Boku, Narikazu
    Kato, Ken
    Shoji, Hirokazu
    BMC CANCER, 2025, 25 (01)
  • [44] A multicenter phase II study of TSU-68, a novel oral multiple tyrosine kinase inhibitor, in patients with metastatic breast cancer progressing despite prior treatment with an anthracycline-containing regimen and taxane
    Yasuhiro Suzuki
    Toshiaki Saeki
    Kenjiro Aogi
    Masakazu Toi
    Hirofumi Fujii
    Kenichi Inoue
    Toru Watanabe
    Yasuhiro Fujiwara
    Yoshinori Ito
    Yuichi Takatsuka
    Hiroji Iwata
    Hitoshi Arioka
    Yutaka Tokuda
    International Journal of Clinical Oncology, 2013, 18 : 590 - 597
  • [45] Multicenter, randomized, open-label Phase II study comparing S-1 alternate-day oral therapy with the standard daily regimen as a first-line treatment in patients with unresectable advanced pancreatic cancer
    Hiroki Yamaue
    Atsushi Shimizu
    Yasuhiro Hagiwara
    Masayuki Sho
    Hiroaki Yanagimoto
    Shoji Nakamori
    Hideki Ueno
    Hiroshi Ishii
    Masayuki Kitano
    Kazuya Sugimori
    Hiroyuki Maguchi
    Shinichi Ohkawa
    Hiroshi Imaoka
    Daisuke Hashimoto
    Kazuki Ueda
    Hiroko Nebiki
    Tatsuya Nagakawa
    Hiroyuki Isayama
    Isao Yokota
    Yasuo Ohashi
    Tetsuhiko Shirasaka
    Cancer Chemotherapy and Pharmacology, 2017, 79 : 813 - 823
  • [46] A multicenter phase II study of TSU-68, a novel oral multiple tyrosine kinase inhibitor, in patients with metastatic breast cancer progressing despite prior treatment with an anthracycline-containing regimen and taxane
    Suzuki, Yasuhiro
    Saeki, Toshiaki
    Aogi, Kenjiro
    Toi, Masakazu
    Fujii, Hirofumi
    Inoue, Kenichi
    Watanabe, Toru
    Fujiwara, Yasuhiro
    Ito, Yoshinori
    Takatsuka, Yuichi
    Iwata, Hiroji
    Arioka, Hitoshi
    Tokuda, Yutaka
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2013, 18 (04) : 590 - 597
  • [47] Anlotinib plus docetaxel versus docetaxel as second-line treatment for advanced non-small cell lung cancer (NSCLC): Updated results from a phase I/II study.
    Fang, Yong
    Pan, Hongming
    Shou, Jiawei
    Hong, Wei
    Guo, Qunyi
    Yang, Xinmei
    Zhu, Dan
    Chen, Jun
    Lu, Liqin
    Rao, Chuangzhou
    Lan, Fen
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [48] ADXS11-001 immunotherapy targeting HPV-E7: Preliminary survival data from a phase II study in Indian women with recurrent/refractory cervical cancer
    Basu, Partha
    Petit, Robert G.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [49] Updated analysis of DESTINY-Gastric02: A phase II singlearm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable/ metastatic gastric/gastroesophageal junction (GEJ) cancer who progressed on or after trastuzumab-containing regimen
    Ku, G. Y.
    Di Bartolomeo, M.
    Smyth, E.
    Chau, I.
    Park, H.
    Siena, S.
    Lonardi, S.
    Wainberg, Z. A.
    Ajani, J. A.
    Chao, J.
    Barlaskar, F.
    Kawaguchi, Y.
    Qin, A.
    Singh, J.
    Meinhardt, G.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1100 - S1100
  • [50] Pemigatinib in Chinese patients with advanced/metastatic or surgically unresectable cholangiocarcinoma including FGFR2 fusion or rearrangement: Updated data from an open-label, single-arm, multicenter phase II study (CIBI375A201 study).
    Shi, Guoming
    Huang, Xiaoyong
    Wen, Tianfu
    Song, Tianqiang
    Kuang, Ming
    Mou, Haibo
    Bao, Lequn
    Zhao, Hai-Tao
    Zhao, Hong
    Feng, Xielin
    Zhang, Bixiang
    Peng, Tao
    Zhang, Yubao
    Li, Xiangcheng
    Yu, Hongsheng
    Cao, Yu
    Luo, Yang
    Chen, Mingxia
    Fan, Jia
    Zhou, Jian
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16183 - E16183
12345